Hannah M Lee1, Bubu A Banini2. 1. Department of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University Medical Center, 1200 E. Broad St, 14th floor, PO Box 980341, Richmond, VA, 23298, USA. Hannah.Lee@vcuhealth.org. 2. Department of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University Medical Center, 1200 E. Broad St, 14th floor, PO Box 980341, Richmond, VA, 23298, USA.
Abstract
PURPOSE OF REVIEW: Chronic HBV (CHB) remains a global public health problem with over 257 million people chronically infected worldwide. Without appropriate management, 20% of individuals infected with CHB will die from complications of cirrhosis, liver failure, or hepatocellular carcinoma (HCC). Despite an effective vaccination to prevent infection, HBV has yet to be successfully eradicated globally. Current treatments can only control and suppress the virus but cannot cure. Updates in the management of chronic HBV will be reviewed, including latest treatments and treatment strategies as well as potential curative therapeutic agents in clinical trial. RECENT FINDINGS: A new nucleotide analogue drug, tenofovir alafenamide fumarate (TAF), has been added to the HBV therapeutic armamentarium. A more potent drug showing non-inferiority, TAF has shown to improve renal and bone laboratory safety parameters compared to TDF. In addition, new treatment recommendations have been made for both general and special populations including pregnancy and HBV reactivation. There is growing data supporting the importance of antiviral therapy in patients with advanced liver disease and liver decompensation which has resulted in improved outcomes. In addition, at least 30 potential therapeutics are in clinical trials in the pursuit of curative treatments for chronic HBV with the goal of "functional cure." CHB remains a global public health problem with complications including cirrhosis, liver failure, and HCC. Current antiviral therapy can cause reversal of liver disease, improve outcomes, and prevent complications such as reactivation but still requires long-term use. Curative treatments for HBV are greatly needed with promising curative drugs in early phase studies.
PURPOSE OF REVIEW: Chronic HBV (CHB) remains a global public health problem with over 257 million people chronically infected worldwide. Without appropriate management, 20% of individuals infected with CHB will die from complications of cirrhosis, liver failure, or hepatocellular carcinoma (HCC). Despite an effective vaccination to prevent infection, HBV has yet to be successfully eradicated globally. Current treatments can only control and suppress the virus but cannot cure. Updates in the management of chronic HBV will be reviewed, including latest treatments and treatment strategies as well as potential curative therapeutic agents in clinical trial. RECENT FINDINGS: A new nucleotide analogue drug, tenofovir alafenamide fumarate (TAF), has been added to the HBV therapeutic armamentarium. A more potent drug showing non-inferiority, TAF has shown to improve renal and bone laboratory safety parameters compared to TDF. In addition, new treatment recommendations have been made for both general and special populations including pregnancy and HBV reactivation. There is growing data supporting the importance of antiviral therapy in patients with advanced liver disease and liver decompensation which has resulted in improved outcomes. In addition, at least 30 potential therapeutics are in clinical trials in the pursuit of curative treatments for chronic HBV with the goal of "functional cure." CHB remains a global public health problem with complications including cirrhosis, liver failure, and HCC. Current antiviral therapy can cause reversal of liver disease, improve outcomes, and prevent complications such as reactivation but still requires long-term use. Curative treatments for HBV are greatly needed with promising curative drugs in early phase studies.
Authors: Thomas Berg; Karl-Georg Simon; Stefan Mauss; Eckart Schott; Renate Heyne; Dietmar M Klass; Christoph Eisenbach; Tania Mara Welzel; Reinhart Zachoval; Gisela Felten; Julian Schulze-Zur-Wiesch; Markus Cornberg; Marjoleine L Op den Brouw; Belinda Jump; Hans Reiser; Lothar Gallo; Tobias Warger; Jörg Petersen Journal: J Hepatol Date: 2017-07-21 Impact factor: 25.083
Authors: Robert S Brown; Brian J McMahon; Anna S F Lok; John B Wong; Ahmed T Ahmed; Mohamed A Mouchli; Zhen Wang; Larry J Prokop; Mohammad Hassan Murad; Khaled Mohammed Journal: Hepatology Date: 2015-11-13 Impact factor: 17.425
Authors: S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao Journal: Hepatol Int Date: 2015-11-13 Impact factor: 6.047
Authors: Mahmoud F Dondeti; Mohamed S Abdelkhalek; Hosam M El-Din Elezawy; Walaa F Alsanie; Bassem M Raafat; Amira M Gamal-Eldeen; Roba M Talaat Journal: J Appl Biomed Date: 2022-01-12 Impact factor: 1.797
Authors: Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies Journal: Virus Res Date: 2020-05-30 Impact factor: 3.303
Authors: Joseph F Grippo; Ilia Folitar; Sharon Passe; Qiudi Jiang; Ignacio Rodriguez; Scott H Fettner; Elizabeth Calleja Journal: Clin Transl Sci Date: 2021-04-09 Impact factor: 4.689